Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindu.com - The Hindu Bureau - Conventional financing remains a hurdle for pharma innovation, say industry leaders
Conventional financing remains a hurdle for pharma innovation, say industry leaders
The Hindu

India has the potential to move up the pharmaceutical value chain from its existing dominant position as a major generics manufacturer globally to a big player in innovation, particularly drug discovery, if such efforts are supported by adequate…

swissinfo.ch - Aylin Elçi - The art of the deal: what are Trump's pharma announcements really worth?
The art of the deal: what are Trump's pharma announcements really worth?
www.swissinfo.ch

On October 10, the White House announced a deal between the United States and the British pharma giant, AstraZeneca, that included a $50 billion (CHF38.8 billion) investment in the US and the creation of 3,600 jobs. The press release also mentioned…

bloomberg.com - Sanne Wass - LEO Pharma Positions for IPO This Year With Investor Meetings
LEO Pharma Positions for IPO This Year With Investor Meetings
Bloomberg

LEO Pharma A/S's leadership has been engaging prospective investors in recent months as it advances preparations for a potential stock market listing this year, Chief Executive Officer Christophe Bourdon said. The Danish drugmaker, which focuses on…

globenewswire.com - Zealand Pharma - Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
GlobeNewswire

Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings…

axios.com - Peter Sullivan - Trump officials try to make peace with pharma
Trump officials try to make peace with pharma
Axios

Senior Trump administration health officials sought to smooth over simmering tensions with the drug industry at an industry forum on Tuesday — but with limited success. Why it matters: Drug companies have been frustrated navigating President…

deccanchronicle.com - B. Krishna Mohan - Pharma Sector Shifting to AI-Led Innovation
Pharma Sector Shifting to AI-Led Innovation
Deccan Chronicle

Hyderabad:The pharmaceutical industry is shifting from linear drug development models to an integrated innovation architecture that combines advanced biology, artificial intelligence and digitally enabled manufacturing, according to a report. The…

thehindubusinessline.com - Next round of growth in pharma, life sciences will be in high value products: CEOs
Next round of growth in pharma, life sciences will be in high value products: CEOs
BusinessLine

To further harness global opportunity in pharma and life sciences, Indian industry needs to move up on the value chain to become a capability leader with focus on high-value products, according to industry captains. The journey towards this end has…

thehindubusinessline.com - Platform models gaining ground in pharma R&D: Report
Platform models gaining ground in pharma R&D: Report
BusinessLine

Rising scientific complexity is pushing companies to redesign R&D (research and development) around platform-based models rather than one-off products, according to a study by EY-Parthenon India. The report – Pharma's New Architecture: Where…

marketbeat.com - NewAmsterdam Pharma (NAMS) Projected to Post Earnings on Wednesday
NewAmsterdam Pharma (NAMS) Projected to Post Earnings on Wednesday
MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

marketbeat.com - Heartland Advisors Inc. Purchases New Shares in Royalty Pharma PLC $RPRX
Heartland Advisors Inc. Purchases New Shares in Royalty Pharma PLC $RPRX
MarketBeat

Heartland Advisors Inc. acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 96,553…

marketbeat.com - BridgeBio Pharma, Inc. $BBIO Shares Sold by Readystate Asset Management LP
BridgeBio Pharma, Inc. $BBIO Shares Sold by Readystate Asset Management LP
MarketBeat

Readystate Asset Management LP reduced its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 51.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 117,379…

marketbeat.com - Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO
Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO
MarketBeat

Cibc World Market Inc. acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,708 shares of…

marketbeat.com - Smbc Nikko Sec. Upgrades Astellas Pharma (OTCMKTS:ALPMY) to 'Hold'
Smbc Nikko Sec. Upgrades Astellas Pharma (OTCMKTS:ALPMY) to 'Hold'
MarketBeat

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) was upgraded by stock analysts at Smbc Nikko Sec. to a 'hold' rating in a report released on Monday, Zacks.com reports. A number of other research analysts also recently commented on ALPMY. Zacks…

seekingalpha.com - Bhavneesh Sharma - Aquestive Therapeutics: A Forensic Analysis Of The Anaphylm CRL (NASDAQ:AQST)
Aquestive Therapeutics: A Forensic Analysis Of The Anaphylm CRL (NASDAQ:AQST)
Seeking Alpha

Aquestive Therapeutics is rated Strong Buy with a $7 target, implying 92% upside, driven by regulatory clarity and mispricing. The FDA's Complete Response Letter for Anaphylm is viewed as a 12-month delay, not a fundamental risk, with a 99.2%…

marketbeat.com - Ascendis Pharma A/S $ASND Shares Sold by Readystate Asset Management LP
Ascendis Pharma A/S $ASND Shares Sold by Readystate Asset Management LP
MarketBeat

Readystate Asset Management LP lessened its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 84.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm…

Receive a Daily briefing on Pharma Industry News

Get Started